

Please type a plus sign (+) inside this box → ☒



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to the collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/069,455
		Filing Date	07/08/2002
		First Named Inventor	Erez
		Group Art Unit	1614
		Examiner Name	
Sheet	2	Of	2
		Attorney Docket Number 02/23383	
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Olshausen et al, "Sudden Cardiac Death While Wearing a Holter Monitor", <i>Am J Cardiol</i> , 67(5):381-386, 1991 (Abstract)	
		Williams, V., "Classifying Antiarrhythmic Actions: By Facts or Speculation", <i>J Clin Pharmacol</i> , 32(11):964-977, 1992 (Abstract)	
		(No author listed) "Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of arrhythmia Suppression after Myocardial Infarction. Cardia Arrhythmia Suppression Trial (CAST) Investigators", <i>N.Engl J Med</i> , 321(6):406-412, 1989 (Abstract)	
		Manoach et al, "Spontaneous Termination of Electrically Induced Ventricular Fibrillation", <i>Progress in Electrocardiology</i> , Glasgow, Ed. P. MacFarlane. Pitman Medical, pp 361-365, 1979	
		Manoach et al, "Spontaneous Termination and Initiation of Ventricular Fibrillation as a Function of Heart Size, Age, Autonomic Autoregulation, and drugs: A Comparative Study on Different Species of Different Age", <i>Heart Vessels</i> , Suppl.2:56-68, 1987	
		Manoach et al, "Reduction of Infarct Size Following Acute Coronary Occlusion by Augmenting Collateral Blood Supply Induced by Infusion of Tricyclic Antidepressants", <i>Heart Vessels</i> , 3:80-83, 1987	
		Manoach et al, "The Cardio-Protective Features of Tricyclic Antidepressants", <i>Gen. Pharmac.</i> , 20(3):269-275, 1989	
		Manoach et al, "Propertis Required for Self-Ventricular Defibrillation: Influence of Age and Drugs", <i>Cardiology in the Elderly</i> , 1:337-344, 1993	
		Manoach et al, "The Role of Catecholamines on Intercellular Coupling, Myocardial Cell Synchronization and Self Ventricular Defibrillation", <i>Molecular and Cellular Biochemistry</i> , 147:181-185, 1995	
		Erez et al, "Dibenzazepines and Phenothiazines – A Winding Path to Defibrillatory Antiarrhythmic Agents", <i>Exp. Clin. Cardiol.</i> , 2(1):59-63, 1997	
	Kaverina et al, "New Cardiovascular Drugs among Phenothiazine Derivitives and Related Tricyclic Systems", <i>Sov. Med. Rev. A. Cardiology</i> , 3:81-100, 1991		
Examiner Signature	Date Considered		1/25/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.